查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010931

肝癌治療市場：2026-2032年全球市場預測（依治療方法、癌症類型、給藥途徑、藥物類別、最終用戶和分銷管道分類）

Liver Cancer Drugs Market by Therapy Type, Cancer Type, Administration Route, Drug Class, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年肝癌治療市場價值 41 億美元，預計到 2026 年將成長至 46.7 億美元，複合年成長率為 14.95%，到 2032 年將達到 108.8 億美元。

主要市場統計數據
基準年 2025 41億美元
預計年份：2026年 46.7億美元
預測年份 2032 108.8億美元
複合年成長率 (%) 14.95%

肝臟腫瘤學領域的典範轉移，是由免疫腫瘤學、精準醫學和複雜的管理挑戰的整合所驅動的。

肝癌治療正處於轉折點，其特點是科學的快速進步、臨床範式的轉變以及商業性趨勢的變化。近年來，免疫腫瘤學方法已穩步融入現有的標靶治療治療和細胞毒性療法中，推動了將全身性治療與局部和區域干預相結合的多學科治療路徑的形成。因此，臨床醫生、保險公司和製藥公司正在重新思考治療流程，以期在克服醫療資源獲取障礙和複雜的報銷環境的同時，最佳化治療效果。

免疫腫瘤學、精準診斷和新的給藥模式的突破如何重新定義肝癌的治療和給藥方式。

肝癌治療格局已發生翻天覆地的變化，這主要得益於免疫療法、標靶小分子藥物和聯合治療策略的突破性進展。查核點抑制劑與抗血管新生藥物的聯合應用徹底革新了一線治療方案，而針對特定分子異常的標靶抑制劑則為以往治療不足的患者群體提供了更多選擇。同時，診斷準確性的提高，包括分子譜分析的廣泛應用，使得患者與治療方法的匹配更加精準，加速了向個人化醫療的轉變。

評估 2025 年關稅變化將如何加劇供應鏈脆弱性、影響價格結構並加速以本地為中心的製造策略。

計劃於2025年實施的關稅徵收和貿易政策調整，正對肝癌治療生態系統產生累積影響，暴露出全球藥品供應鏈和採購慣例中原有的脆弱性。活性成分、輔料和成品進口關稅的提高，可能會增加生產商和經銷商的接收成本，促使他們重新評估籌資策略並調整商業定價模式。因此，醫療服務提供者和保險公司將面臨價格壓力，這可能會影響藥物選擇和患者用藥計劃。

透過全面的細分分析，闡明治療方法、癌症亞型、給藥途徑和通路如何影響治療的採用。

細分市場分析透過將市場分類為治療方法類型、癌症亞型、給藥途徑、藥物類別、最終用戶和分銷管道等框架，為理解肝癌治療的需求和供應提供了精準的觀點。依治療方法類型（例如化療、免疫療法、放射線治療和標靶治療療法）進行分類，可以清楚觀察每個治療階段的臨床結果和資源消耗。同樣，按癌症類型（例如膽管癌、肝母細胞瘤和肝細胞癌）進行細分，可以揭示未滿足需求的差異、基於年齡和生物學特徵的治療選擇，以及利基創新機會。

影響美洲、歐洲、中東和非洲以及亞太地區治療方法引進和提供的地區差異和促進因素。

區域趨勢對治療方法的可近性、監管管道和商業策略有顯著影響，美洲、歐洲、中東和非洲以及亞太地區之間存在著明顯的差異。在美洲，先進的腫瘤學基礎設施、廣泛的臨床試驗網路和完善的醫保報銷機制使得新型系統性療法能夠相對快速地引入市場。另一方面，支付方的審查和成本效益評估正日益影響治療方法的生命週期管理。專科醫療中心的地理集中也有利於複雜病例的重症監護，但在資源匱乏的地區，醫療資源的可近性仍存在差距。

企業策略趨勢表明，研發合作、投資組合多元化和真實世界數據策略正在塑造競爭地位。

肝癌治療領域的關鍵趨勢表明，策略性研發投資、合作以及生命週期管理相結合，旨在實現長期成長並保持臨床意義。製藥和生物技術公司越來越重視利用互補作用機制的聯合治療，同時投資於伴隨診斷，以最佳化患者篩選並向支付方證明其價值。大型跨國公司與專業生技公司之間的策略合作十分普遍，這有助於加快新藥上市速度並分擔研發風險。

為產業領導者提供可操作的策略指南，以加強供應鏈韌性、精準診斷和以價值為中心的商業化方法。

產業領導者必須採取一系列切實可行的措施，以應對肝癌治療領域快速變化的局面，確保患者能夠持續獲得治療，並實現商業性的永續發展。首先，他們應優先考慮供應鏈多元化和策略性供應商選擇，以減少對單一供應商的依賴，並最大限度地降低貿易政策波動和原料短缺的風險。投資區域製造能力和靈活的生產平台，可以提高韌性，同時加快關鍵療法的上市速度。

調查方法，結合專家進行的初步研究和嚴格的二次研究，以檢驗臨床、監管和商業性的發現。

本研究採用混合方法，將專家的初步意見與全面的二次分析相結合，從而對肝癌治療提供了可靠且令人信服的觀點。初步研究包括對臨床意見領袖、腫瘤藥劑師、保險公司代表和高級商業管理人員進行結構化訪談和討論，以了解真實的臨床實踐模式、報銷趨勢和策略重點。這些專家見解用於闡述文獻分析中湧現的趨勢和檢驗。

強調需要將科學創新、營運韌性和以支付方為中心的證據結合起來，最終實現整合，將治療方面的進步與患者的益處聯繫起來。

總之，肝癌治療正受到多種因素的共同影響而重塑，包括免疫腫瘤學和標靶治療的科學創新、不斷改進的給藥和治療方式，以及貿易政策和區域醫療資源分配不均等外部壓力。這些因素在為改善患者預後創造新機會的同時，也帶來了營運和報銷方面的複雜性，需要產業、醫療服務提供者和支付方協調應對。最終，這將形成一個更動態、以患者為中心的環境，在這個環境中，精準性、柔軟性和實證商業化都備受重視。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 肝癌治療市場（依治療方法分類）

  • 化療
  • 免疫療法
  • 放射線治療
  • 分子標靶治療

第9章 依癌症類型分類的肝癌治療市場

  • 膽管癌
  • 肝母細胞瘤
  • 肝細胞癌（HCC）

第10章：依給藥途徑分類的肝癌治療市場

  • 靜脈
  • 口服
  • 皮下注射

第11章 肝癌治療市場：依藥物類別分類

  • 細胞毒性藥物
  • 單株抗體
  • 蛋白酪氨酸激酶抑制劑（TKIs）

第12章 肝癌治療藥物市場：依最終用戶分類

  • 居家醫療
  • 醫院
  • 專科診所

第13章 肝癌治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 肝癌治療藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 肝癌治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 肝癌治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國肝癌治療市場

第18章：中國肝癌治療藥物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agenus Inc.
  • AstraZeneca AB
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Can-Fite BioPharma Ltd.
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • CStone Pharmaceuticals
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • Hoffmann-La Roche Inc.
  • Innovent Biologics, Inc.
  • Ipsen SA
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Roche Holding AG（F. Hoffmann-La Roche Ltd）
  • Zai Lab Limited
Product Code: MRR-434CCDA05287

The Liver Cancer Drugs Market was valued at USD 4.10 billion in 2025 and is projected to grow to USD 4.67 billion in 2026, with a CAGR of 14.95%, reaching USD 10.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.10 billion
Estimated Year [2026] USD 4.67 billion
Forecast Year [2032] USD 10.88 billion
CAGR (%) 14.95%

An evolving therapeutic paradigm in liver oncology driven by immuno-oncology integration, precision medicine, and complex delivery challenges

Liver cancer therapeutics are at an inflection point, characterized by rapid scientific advances, shifting clinical paradigms, and evolving commercial dynamics. Recent years have seen the steady integration of immuno-oncology approaches alongside established targeted therapies and cytotoxic regimens, prompting multidisciplinary care pathways that blend systemic treatments with locoregional interventions. As a result, clinicians, payers, and manufacturers are re-evaluating treatment algorithms to optimize outcomes while navigating access barriers and complex reimbursement environments.

Transitioning from historical monotherapy models to combination regimens has created new opportunities and new complexities for clinical development, regulatory approval, and market deployment. Patient stratification through molecular profiling and the growing importance of real-world evidence are reshaping trial design and post-approval evidence generation. Consequently, strategic stakeholders must balance innovation with pragmatic considerations such as supply chain resilience, pricing strategies, and stakeholder education to ensure that therapeutic advances translate into measurable patient benefit.

Ultimately, the modern landscape demands an integrated perspective that accounts for evolving science, multi-stakeholder incentives, and the operational realities of delivering care across diverse settings. This introduction sets the stage for a deeper exploration of the disruptive shifts, policy influences, segmentation nuances, geographic differentials, competitive maneuvers, and recommended actions that follow in this executive summary.

How immuno-oncology breakthroughs, precision diagnostics, and novel administration models are collectively redefining liver cancer treatment and care delivery

The liver cancer treatment landscape has undergone transformative shifts driven by breakthroughs in immunotherapy, targeted small molecules, and combination strategies. Checkpoint inhibition paired with antiangiogenic agents has altered frontline care pathways, while targeted inhibitors for specific molecular aberrations have expanded options for previously underserved subpopulations. Concurrently, improvements in diagnostic precision, including more widespread molecular profiling, have made it possible to match patients to therapies with greater accuracy, accelerating the move toward personalized regimens.

As clinical benefits have been demonstrated in both survival and tolerability for select combinations, payer and provider systems are recalibrating care pathways to incorporate these innovations. This recalibration has prompted new collaborations between oncology centers, diagnostic laboratories, and specialty pharmacies to deliver integrated care. Moreover, the growth of oral targeted therapies and subcutaneous formulations is changing administration dynamics, enabling more outpatient and home-based care models that reduce hospital burden and improve patient convenience.

In parallel, regulatory frameworks are evolving to accommodate adaptive trial designs and accelerated approval pathways, which has encouraged sponsors to pursue novel endpoints and surrogate markers. As a result, the therapeutic trajectory is defined not only by scientific advances but by systemic shifts in care delivery, regulatory interaction, and commercial execution that together are redefining what constitutes best-in-class treatment for liver malignancies.

Assessment of how 2025 tariff shifts are compounding supply chain fragility, influencing pricing structures, and accelerating localized manufacturing strategies

The introduction of tariffs and trade policy shifts in 2025 has had a cumulative impact on the liver cancer therapeutic ecosystem by accentuating pre-existing vulnerabilities in global pharmaceutical supply chains and procurement practices. Increased import duties on active pharmaceutical ingredients, excipients, and finished formulations can raise landed costs for manufacturers and distributors, prompting reassessment of sourcing strategies and potential adjustments to commercial pricing models. In turn, healthcare providers and payers may face pricing pressures that influence formulary decisions and patient access programs.

Moreover, tariffs can accelerate efforts to regionalize manufacturing and strengthen local supply resilience, prompting investment in geographically diversified production capacity and strategic stockpiling. While reshoring and nearshoring efforts can mitigate future disruption risk, they also introduce short-term capital expenditures and regulatory complexities associated with establishing compliant manufacturing sites. Consequently, market entrants and incumbents must weigh the trade-offs between cost, agility, and compliance in planning their manufacturing footprints.

Furthermore, trade policy volatility may affect the cadence of clinical trial supplies and the availability of specialized assays required for patient selection, with potential downstream impacts on enrollment and study timelines. For stakeholders operating across multiple jurisdictions, tariffs add a layer of strategic uncertainty that underscores the importance of flexible contracting, robust supplier qualification, and proactive engagement with payers to preserve patient access amidst shifting cost structures.

Comprehensive segmentation insights revealing how therapy modalities, cancer subtypes, administration routes, and distribution pathways shape treatment adoption

Segmentation analyses provide a nuanced lens to understand therapeutic demand and delivery in liver cancer by framing the market across therapy type, cancer subtype, administration route, drug class, end user, and distribution channel. When treatments are categorized by therapy type such as chemotherapy, immunotherapy, radiation therapy, and targeted therapy, one can observe distinct clinical trajectories and resource implications across lines of care. Similarly, segmenting by cancer type-covering cholangiocarcinoma, hepatoblastoma, and hepatocellular carcinoma-illuminates differential unmet needs, age- and biology-driven treatment choices, and opportunities for niche innovation.

Administration route segmentation, which includes intravenous, oral, and subcutaneous options, reveals how delivery modality affects patient adherence, outpatient utilization, and the economics of care. Examination by drug class differentiates cytotoxic agents from monoclonal antibodies and tyrosine kinase inhibitors, each bringing a unique safety, monitoring, and development profile that shapes clinical adoption. End user segmentation across home care, hospitals, and specialty clinics highlights the operational pathways through which therapies are delivered and the corresponding requirements for patient education and monitoring.

Finally, distribution channel analysis, spanning hospital pharmacy, online pharmacy, and retail pharmacy, sheds light on access pathways, fulfillment complexity, and the evolving role of digital and specialty dispensing models. Taken together, these segmentation perspectives enable stakeholders to identify targeted commercialization strategies, prioritize evidence generation in subpopulations, and design delivery models that align with clinical practice and patient preferences.

Regional differentiators and access enablers across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence therapeutic adoption and delivery

Regional dynamics exert a strong influence on therapy availability, regulatory pathways, and commercial strategies, with clear distinctions across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, advanced oncology infrastructures, broad clinical trial networks, and progressive reimbursement frameworks have enabled relatively rapid adoption of novel systemic regimens, while payer scrutiny and cost-effectiveness evaluations increasingly shape lifecycle management of therapies. Geographic concentration of specialty centers also facilitates centralized care for complex cases, but disparities in access persist in under-resourced areas.

Within Europe, Middle East & Africa, heterogeneous regulatory regimes and variable healthcare financing models produce a patchwork of access and uptake. High-income European markets often see quicker alignment with guideline recommendations and broader reimbursement pathways, whereas regions with constrained resources must balance high-cost innovations against competing health priorities, driving interest in tiered pricing and access programs. The Middle East and parts of Africa face distinct infrastructure and diagnostic capacity challenges that require tailored implementation approaches.

Asia-Pacific exhibits a spectrum from advanced market adoption, driven by large public health systems and active domestic manufacturing, to emerging markets where diagnostic capacity and distribution logistics are still expanding. Regulatory modernization efforts and local clinical development partnerships are notable trends in the region, supporting both global clinical programs and regionally specific therapeutic innovations. Across all regions, cross-border collaboration, technology-enabled care models, and adaptive reimbursement mechanisms are emerging as critical enablers of broader patient access.

Strategic corporate patterns showing how R&D alliances, portfolio diversification, and real-world evidence strategies are shaping competitive positioning

Key corporate behaviors in the liver cancer therapeutics arena reveal a mix of strategic R&D investment, partnering activity, and lifecycle management aimed at sustaining long-term growth and clinical relevance. Pharmaceutical and biotechnology companies are increasingly prioritizing combination regimens that leverage complementary mechanisms of action, while also investing in companion diagnostics to improve patient selection and demonstrate value to payers. Strategic alliances between large multinationals and specialist biotech firms are commonplace, enabling speed-to-market for novel agents and the sharing of development risk.

Pipeline diversification is a central theme, with firms balancing small-molecule kinase inhibitors and cytotoxic programs alongside biologics, antibody-drug conjugates, and immune-modulating platforms. Companies are also focused on developing formulations and administration routes that support outpatient care, including oral and subcutaneous options that align with shifting provider preferences. From a commercial perspective, leaders are expanding patient support services and value-based arrangements to mitigate access hurdles and strengthen payer relationships.

Mergers and acquisitions, as well as selective licensing deals, remain important tools for accelerating access to promising assets and augmenting therapeutic portfolios. In parallel, firms are placing greater emphasis on real-world evidence generation and post-marketing surveillance to refine positioning, manage safety considerations, and inform iterative regulatory submissions. Collectively, these corporate strategies underscore a pragmatic convergence of scientific ambition and commercial discipline.

Actionable strategic directives for industry leaders to strengthen supply resilience, precision diagnostics, and value-focused commercialization approaches

Industry leaders must adopt a set of pragmatic, actionable measures to navigate the rapidly evolving liver cancer therapeutics landscape and to ensure sustainable patient access and commercial viability. First, supply chain diversification and strategic supplier qualification should be prioritized to reduce dependency on single-source suppliers and to minimize the disruption risk posed by trade policy fluctuations or raw material constraints. Investments in regional manufacturing capacity and flexible production platforms can both improve resilience and shorten time-to-market for critical therapies.

Second, stakeholders should invest in robust molecular diagnostic capabilities and companion diagnostic partnerships to enable precise patient selection, which enhances clinical outcomes and strengthens reimbursement cases. Third, value-based contracting and outcomes-based pricing models should be pursued in collaboration with payers and providers to align payment with real-world performance, thereby mitigating pricing pressure while facilitating access. Fourth, cross-sector collaborations that integrate digital health tools, telemedicine, and remote monitoring can expand reach to underserved populations and support adherence to oral or subcutaneous regimens.

Finally, companies should emphasize transparent engagement with regulators and payers early in development to align on evidentiary requirements and to design pragmatic post-approval evidence-generation plans. By combining operational resilience with clinically focused commercialization strategies, industry leaders can accelerate uptake of innovative therapies while safeguarding long-term sustainability.

Methodological framework combining expert primary research with rigorous secondary synthesis to validate clinical, regulatory, and commercial insights

This research synthesis is grounded in a mixed-methods approach that triangulates primary expert input with comprehensive secondary analysis to provide a robust, defensible perspective on liver cancer therapeutics. Primary research consisted of structured interviews and consultations with clinical thought leaders, oncology pharmacists, payer representatives, and senior commercial executives to capture real-world practice patterns, reimbursement dynamics, and strategic priorities. These expert insights were used to contextualize trends and validate themes emerging from documentary analysis.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to map therapeutic advances, trial outcomes, and evidence trajectories. Information from public health agencies and specialty society guidelines was synthesized to understand standard-of-care shifts and diagnostic adoption patterns. Data quality was ensured through cross-referencing of multiple independent sources and iterative validation with subject matter experts.

Limitations of the methodology include the evolving nature of clinical evidence and policy environments, which may change subsequent to the research window. To mitigate this, the approach emphasizes transparent documentation of data provenance and encourages ongoing monitoring of regulatory decisions and major clinical readouts. The methodology balances depth and breadth to support strategic decision-making while acknowledging the need for periodic updates as the field advances.

Final synthesis emphasizing the need to align scientific innovation, operational resilience, and payer-focused evidence to translate therapeutic advances into patient benefit

In conclusion, liver cancer therapeutics are being reshaped by convergent forces: scientific innovation in immuno-oncology and targeted agents, evolving care delivery and administration modalities, and external pressures such as trade policy and regional access disparities. These forces are producing new opportunities for improved patient outcomes while also introducing operational and reimbursement complexities that require coordinated responses from industry, providers, and payers. The net effect is a more dynamic, patient-centric landscape that rewards precision, flexibility, and evidence-driven commercialization.

Moving forward, stakeholders that prioritize diagnostic integration, supply chain resilience, and payer-aligned value demonstration will be better positioned to translate innovation into durable clinical and commercial success. Moreover, adaptive regulatory engagement and strategic partnerships-both clinical and commercial-will remain critical levers for accelerating patient access. Ultimately, the ability to harmonize scientific promise with pragmatic implementation will determine which therapies achieve sustained impact for the diverse populations affected by liver malignancies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Cancer Drugs Market, by Therapy Type

  • 8.1. Chemotherapy
  • 8.2. Immunotherapy
  • 8.3. Radiation Therapy
  • 8.4. Targeted Therapy

9. Liver Cancer Drugs Market, by Cancer Type

  • 9.1. Cholangiocarcinoma
  • 9.2. Hepatoblastoma
  • 9.3. Hepatocellular Carcinoma (HCC)

10. Liver Cancer Drugs Market, by Administration Route

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Liver Cancer Drugs Market, by Drug Class

  • 11.1. Cytotoxic Agents
  • 11.2. Monoclonal Antibodies
  • 11.3. Tyrosine Kinase Inhibitors (TKIs)

12. Liver Cancer Drugs Market, by End User

  • 12.1. Home Care
  • 12.2. Hospital
  • 12.3. Specialty Clinic

13. Liver Cancer Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Liver Cancer Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Liver Cancer Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Liver Cancer Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Liver Cancer Drugs Market

18. China Liver Cancer Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Agenus Inc.
  • 19.6. AstraZeneca AB
  • 19.7. AstraZeneca PLC
  • 19.8. Bayer AG
  • 19.9. BeiGene, Ltd.
  • 19.10. Bristol-Myers Squibb Company
  • 19.11. Can-Fite BioPharma Ltd.
  • 19.12. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • 19.13. CStone Pharmaceuticals
  • 19.14. Eisai Co., Ltd.
  • 19.15. Eli Lilly and Company
  • 19.16. Exelixis, Inc.
  • 19.17. Hoffmann-La Roche Inc.
  • 19.18. Innovent Biologics, Inc.
  • 19.19. Ipsen SA
  • 19.20. Jiangsu Hengrui Medicine Co., Ltd.
  • 19.21. Merck & Co., Inc.
  • 19.22. Pfizer Inc.
  • 19.23. Roche Holding AG (F. Hoffmann-La Roche Ltd)
  • 19.24. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. GCC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 134. GCC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. GCC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. GCC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. G7 LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. G7 LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 155. G7 LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. G7 LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. G7 LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. NATO LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. NATO LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 162. NATO LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 163. NATO LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. NATO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)